

Angelica Cuapio Gomez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6917751/publications.pdf>

Version: 2024-02-01

22
papers

5,615
citations

623734

14
h-index

713466

21
g-index

26
all docs

26
docs citations

26
times ranked

11273
citing authors

#	ARTICLE	IF	CITATIONS
1	T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. <i>Haematologica</i> , 2022, 107, 1000-1003.	3.5	14
2	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	4.4	19
3	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. <i>Molecular Medicine</i> , 2022, 28, 20.	4.4	18
4	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. <i>Molecular Medicine</i> , 2022, 28, 54.	4.4	18
5	The Karolinska <scp>KI</scp>/K <scp>COVID</scp>â€19 immune atlas: An open resource for immunological research and educational purposes. <i>Scandinavian Journal of Immunology</i> , 2022, 96, .	2.7	4
6	Long-COVID in children and adolescents: a systematic review and meta-analyses. <i>Scientific Reports</i> , 2022, 12, .	3.3	203
7	Activated Natural Killer Cells Hit Neurogenesis in the Aging Brain. <i>Neuroscience Bulletin</i> , 2021, 37, 1072-1074.	2.9	6
8	More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 16144.	3.3	1,358
9	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. <i>EBioMedicine</i> , 2021, 74, 103705.	6.1	161
10	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020, 183, 158-168.e14.	28.9	1,561
11	Natural killer cell immunotypes related to COVID-19 disease severity. <i>Science Immunology</i> , 2020, 5, .	11.9	344
12	MAIT cell activation and dynamics associated with COVID-19 disease severity. <i>Science Immunology</i> , 2020, 5, .	11.9	147
13	ACE2: the molecular doorway to SARS-CoV-2. <i>Cell and Bioscience</i> , 2020, 10, 148.	4.8	82
14	Cell-Mediated Immune Responses and Immunopathogenesis of Human Tick-Borne Encephalitis Virus-Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2174.	4.8	27
15	The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell Development. <i>Frontiers in Immunology</i> , 2017, 8, 535.	4.8	30
16	Human CD56bright NK Cells: An Update. <i>Journal of Immunology</i> , 2016, 196, 2923-2931.	0.8	318
17	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. <i>Oncotarget</i> , 2016, 7, 46466-46481.	1.8	19
18	Binding of the Fap2 Protein of <i>Fusobacterium nucleatum</i> to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack. <i>Immunity</i> , 2015, 42, 344-355.	14.3	900

#	ARTICLE	IF	CITATIONS
19	The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. <i>Journal of Autoimmunity</i> , 2015, 58, 12-20.	6.5	68
20	Polyubiquitinated Tristetraprolin Protects from TNF-induced, Caspase-mediated Apoptosis. <i>Journal of Biological Chemistry</i> , 2014, 289, 25088-25100.	3.4	7
21	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1422-1422.	1.4	0
22	Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6. <i>PLoS ONE</i> , 2013, 8, e62376.	2.5	23